Issue 53, 2019

A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Abstract

Despite their attractive properties, internal targeted alpha therapies using 223/224Ra are limited to bone-seeking applications. As there is no suitable chelator available, the search for new carriers to stably bind Ra2+ and to connect it to biological target molecules is necessary. Polyoxopalladates represent a class of compounds where Ra2+ can be easily introduced into the Pd-POM core during a facile one-pot preparation. Due to the formation of a protein corona, the connection to other targeting (bio)macromolecules is possible.

Graphical abstract: A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Supplementary files

Article information

Article type
Communication
Submitted
03 Apr 2019
Accepted
04 Jun 2019
First published
04 Jun 2019

Chem. Commun., 2019,55, 7631-7634

A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

M. Gott, P. Yang, U. Kortz, H. Stephan, H. Pietzsch and C. Mamat, Chem. Commun., 2019, 55, 7631 DOI: 10.1039/C9CC02587A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements